Ellis Katrina L, Watts Gerald F
School of Medicine, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia; School of Biomedical Sciences, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia.
School of Medicine, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia; Department of Cardiology, Lipid Disorders Clinic, Royal Perth Hospital, GPO Box X2213, Perth, WA 6001, Australia.
Cardiol Clin. 2018 May;36(2):287-298. doi: 10.1016/j.ccl.2017.12.010.
Lipoprotein (a) is a low-density lipoprotein-like particle covalently bound to a glycoprotein called apolipoprotein(a) that is under potent genetic control. Plasma levels of lipoprotein (a) vary by up to 1000-fold among individuals, with 1 in 4 having levels that increase the risk of atherosclerotic cardiovascular disease. New evidence supports a causal role for lipoprotein (a) in atherosclerotic cardiovascular disease and aortic valve stenosis. Individuals with elevated lipoprotein (a) have a high life-time burden of atherosclerotic cardiovascular disease. This notion is important for coronary prevention. But is lipoprotein (a) ready for prime-time use in coronary prevention clinics?
脂蛋白(a)是一种与名为载脂蛋白(a)的糖蛋白共价结合的低密度脂蛋白样颗粒，其受强大的基因控制。个体之间脂蛋白(a)的血浆水平差异高达1000倍，四分之一的人的水平会增加动脉粥样硬化性心血管疾病的风险。新证据支持脂蛋白(a)在动脉粥样硬化性心血管疾病和主动脉瓣狭窄中起因果作用。脂蛋白(a)升高的个体一生都有很高的动脉粥样硬化性心血管疾病负担。这一概念对冠心病预防很重要。但脂蛋白(a)是否已准备好在冠心病预防诊所中广泛应用呢？
